Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155645 · ClinicalTrials.gov registry record · Phase 1
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04155645 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 34 participants.
The verdict
NCT04155645, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a Phase I study to assess the safety, tolerability and pharmacokinetics (PK), and pharmacodynamics (PD) of AZD8233, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD8233 in subjects with confirmed dyslipidemia with or without type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG AZD8233 subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2021-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04155645
The ClinicalTrials.gov registry entry for NCT04155645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04155645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04155645 about?
NCT04155645 is a clinical study titled "To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia". This is a Phase I study to assess the safety, tolerability and pharmacokinetics (PK), and pharmacodynamics (PD) of AZD8233, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD8233 in subjects with confirmed dyslipidemia with or without type 2 diabetes.
What is the current status of trial NCT04155645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-11-21. Estimated completion is 2021-06-07.
What interventions are being tested in trial NCT04155645?
The interventions under investigation include: Placebo (DRUG), AZD8233 subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT04155645?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.